Abstract

Amaç: Bu çalışmanın amacı, sistemik juvenil idiyopatik artrit (sJIA) hastalarında takipte persistan poliartiküler hastalığın seyrini öngörebilecek tanı anındaki öngörücüleri belirlemektir.

Gereç ve Yöntemler: Bu retrospektif gözlemsel çalışma Ocak 2002 ile Ağustos 2024 tarihleri ​​arasında Ankara Bilkent Şehir Hastanesi'nde sJIA tanısı almış hastalarda gerçekleştirildi. Kalıcı poliartiküler tutulumu olan ve olmayan sJIA hastalarında demografik, klinik, laboratuvar bulguları ve komplikasyonlar arasındaki ilişki analiz edildi.

Bulgular: sJIA tanısı konulan 56 hastanın 27'sinde (%48,21) monosiklik, 8'inde (%14,28) polisiklik ve 21'inde (%37,50) persistan hastalık seyri vardı. 16 (%28,57) hastada persistan artrit, 11 (%19,64) hastada ise poliartiküler patern gözlendi. Tanı anında poliartiküler tutulum ve diz, kalça, el bileği ve elin küçük eklemlerinin tutulumu persistan poliartiküler artrit ile ilişkiliydi (p<0,001, p<0,001, p=0,001, p<0,001, p=0,003). Ayrıca, steroidlerin, konvansiyonel hastalığı modifiye edici antiromatizmal ilaçların (cDMARD) ve biyolojik hastalığı modifiye edici antiromatizmal ilaçların (bDMARD) kombinasyonunun ve metotreksat, etanersept ve tocilizumabın kullanımı persistan poliartiküler artrit hastalarında daha yaygındı (p=0,018, p=0,027, p=0,006, p=0,018).

Sonuç: sJIA hastalarının yaklaşık %40'ında kalıcı hastalık seyri gelişir. Erken poliartiküler tutulumu olan hastalar kalıcı poliartiküler seyir açısından yakından ve dikkatlice takip edilmelidir.

Keywords: Arthritis, Disease progression, Juvenile, Polyarthritis, Risk factors, Systemic juvenile idiopathic arthritis

References

  1. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision,Edmonton,2001. J Rheumatol. 2004;31(2):390-2.
  2. Lee JJY, Schneider R. Systemic Juvenile Idiopathic Arthritis. Pediatr Clin North Am. 2018;65(4):691-709. https://doi.org/10.1016/j.pcl.2018.04.005
  3. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54(5):1595-601. https://doi.org/10.1002/art.21774
  4. Ambler WG, Nanda K, Onel KB, Shenoi S. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives. Ann Med. 2022 31;54(1):1839-50. https://doi.org/10.1080/07853890.2022.2095431
  5. Nigrovic PA. Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis? Arthritis Rheumatol [Internet]. 2014;66(6):1405-13. https://doi.org/10.1002/art.38615
  6. Tibaldi J, Pistorio A, Aldera E, Puzone L, El Miedany Y, Pal P, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(11):3505-14. https://doi.org/10.1093/rheumatology/keaa240
  7. Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collabora. Arthritis Rheumatol (Hoboken, NJ). 2016;68(3):566-76. https://doi.org/10.1002/art.39332
  8. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929-36. https://doi.org/10.1002/acr.20497
  9. Barut K, Adrovic A, Sahin S, Tarcin G, Tahaoglu G, Koker O, et al. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience. Int J Rheum Dis 2019;22(9):1661-9. https://doi.org/10.1111/1756-185X.13649
  10. Adiguzel Dundar H, Acari C, Turkucar S, Unsal E. Treatment of systemic JIA: When do we need a biologic? Real world data of a single center. Mod Rheumatol. 2021;31(3):684-90. https://doi.org/10.1080/14397595.2020.1761079.
  11. Erkens R, Esteban Y, Towe C, Schulert G, Vastert S. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease. Rheum Dis Clin North Am. 2021;47(4):585-606. https://doi.org/10.1016/j.rdc.2021.06.003
  12. Wallimann M, Bouayed K, Cannizzaro E, Kaiser D, Belot A, Merlin E, et al. Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort. Pediatr Rheumatol. 2023;21(1):1-9. https://doi.org/10.1186/s12969-023-00886-9.
  13. Modesto C, Woo P, García-Consuegra J, Merino R, García-Granero M, Arnal C, et al. Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. Clin Exp Rheumatol. 2001;19(2):211-7.
  14. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658-66. https://doi.org/10.1002/art.24516.
  15. Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis. 2012;71(7):1122-7. https://doi.org/10.1136/annrheumdis-2011-200237.
  16. Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(7):2092-102. https://doi.org/10.1002/art.21119.
  17. Susic GZ, Stojanovic RM, Pejnovic NN, Damjanov NS, Soldatovic II, Jablanovic DB, et al. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study. Clin Exp Rheumatol 2011;29(2):337-44.
  18. Russo RG, Katsicas MM. Patients with Very Early-onset Systemic Juvenile Idiopathic Arthritis Exhibit More Inflammatory Features and a Worse Outcome. J Rheumatol. 2013;40(3):329 LP - 334. https://doi.org/10.3899/jrheum.120386.
  19. Janow G, Schanberg LE, Setoguchi S, Hasselblad V, Mellins ED, Schneider R, et al. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. J Rheumatol. 2016;43(9):1755-62. https://doi.org/10.3899/jrheum.150997.
  20. Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256. https://doi.org/10.1186/s13075-017-1462-2.

Copyright and license

Copyright © 2025 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Uğur Es Y, Çelikel E, Ekici Tekin Z, Ertem Ş, Polat MC, Öztürk D, et al. Predictors of persistent polyarticular involvement in patients with systemic juvenile idiopathic arthritis. Turk J Pediatr Dis [Internet]. 2025 Jul. 28 [cited 2025 Aug. 23];19(4):168-74. Available from: https://turkjpediatrdis.org/article/view/1108